Canadian biotech Cyclica has embarked on a multi - phase partnership with labs aimed at the advancement of drug discovery using AI - augmented technologies . The partnership will see Cyclica use Ligand Express , its cloud - based drug screening platform , to explore off - target profiles of small molecules and deploy advanced imaging technology to develop innovative predictive models for pharmacokinetic properties . It will also use its Differential Drug imaging technology for multi - targeted drug discovery .
Canadian biotech Cyclica has embarked on a multi-phase collaboration with Bayer aimed at the advancement of drug discovery using AI-augmented technologies. The partnership will see Cyclica use Ligand Express, its cloud-based proteome screening platform, to explore off-target profiles of small molecules and deploy advanced AI technology to develop innovative predictive models for pharmacokinetic properties. It will also use its Differential Drug Design technology for multi-targeted drug design.